Neonatal Mortality, Neurodevelopment
Conditions
Keywords
Neurodevelopment, Neonatal kit, Kenya, Cluster Randomized Controlled Trial, Chlorhexidine, ThermoSpot
Brief summary
Each year, more than 3 million neonatal deaths occur worldwide and greater than 200 million children under the age of 5, almost all in low- and middle-income countries, are not fulfilling their developmental potential. The development of the growing brain can be affected through multiple mechanisms including the same insults that are major causes of mortality, namely hypothermia and infection. The first month of life is a crucial period in neurodevelopment (ND). In this study, the investigators propose the home-based use of an integrated evidence-based toolkit to improve health status, reduce the incidence of neonatal insults that may affect brain development, decrease neonatal mortality rate (NMR), and provide early identification of danger signs. The investigators hypothesize that use of the neonatal toolkit will result in an improvement of at least one standard deviation in neurodevelopment as measured at 12 months of age by the Protocol for Child Monitoring Infant and Toddler (PCM-IT) version.
Detailed description
Each year there are over 3 million global neonatal deaths. While significant progress has been made on overall under 5 mortality over the past decade, minimal progress has been made in reducing neonatal deaths and these now represent about 40% of all deaths in children under the age of 5. The majority of neonatal deaths occur in rural areas of developing countries and approximately two thirds are due to infection and complications relating to low birth weight (LBW) and prematurity. Additionally, more than 200 million children under 5 years old, almost all in low- and middle-income countries (LMIC), are not fulfilling their developmental potential. To date, most neonatal intervention trials in LMIC have focused on reducing mortality and little research has been performed on the consequences of severe but non-fatal neonatal insults on neurodevelopment (ND). Subsequently, little is known about interventions that may reduce the risk of long-term neurocognitive sequelae. The first month of life is a critical period in ND in which there is significant neurogenesis, synaptogenesis, and myelination. Stimulation of the infant's brain during this period may have significant downstream positive effects. Development of the growing brain can be affected through multiple mechanisms including the same insults that are major causes of mortality, namely hypothermia and infection. Reducing the incidence of these insults during this period may not only save lives but also save brains and improve ND outcomes.
Interventions
Contents of the neonatal kit: 1. Clean birth kit: sterile blade, a clean plastic square, plastic gloves, hand soap, and cord ties/clamp. 2. 4% Chlorhexidine (CHX) lotion (15 mL) and a bag of cotton balls. 3. Sunflower oil emollient (50 mL) 4. ThermoSpot 5. Mylar infant sleeve 6. Click to heat warmer (http://www.heatinaclick.ca/products/pocket\_size.html) in a fitted cloth pouch. 7. Handheld battery-operated scale with suspended cloth sling. The scale will not be included with the kit but rather one will be issued to each Community Health Worker.
A sub-set of children in the study will receive a neonatal stimulation program either on its own or in combination with the neonatal kit described above. The stimulation program will focus on teaching three key messages to enhance the caregivers' current caregiving practices, and each message is to be integrated into daily activities (e.g. during feeding, bathing, bedtime routines). By integrating the delivery of the interventions into the caregivers' daily routine, no additional time inconvenience will be added to their schedules. The key messages include: 1. Eye contact and talking to children 2. Responsive feeding and caregiving 3. Singing songs, including those with gentle touch
Sponsors
Study design
Eligibility
Inclusion criteria
i. All pregnant women in parts of study clusters covered by CHW program and their home- or facility-born live newborns. ii. Mothers intending to maintain residence in study area for first 12 months of newborn's life.
Exclusion criteria
i. Failure to provide consent to enroll in study (intervention or control clusters).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Neurodevelopment as measured by the Protocol for Child Monitoring - Infant and Toddler version assessment | 12 months of age | The Protocol for Child Monitoring - Infant and Toddler (PCM-IT) version was designed in Kenya to assess neurodevelopment in resource-limited settings. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of omphalitis | Day 1 (or as soon as possible after notification of birth), 3, 7, 14, and 28 of life | Incidence of omphalitis where omphalitis is defined as: 1. None (no redness or swelling) 2. Mild (inflammation limited to the cord stump) 3. Moderate (inflammation extending less than 2cm to the skin at the base of the cord stump) 4. Severe (inflammation extending more than 2cm from the cord stump) |
| Incidence of severe infection | Day 1 (or as soon as possible after notification of birth), 3, 7, 14, and 28 of life | Defined as: Convulsions OR fast breathing (60 breaths per minute or more) OR severe chest indrawing OR movement only when stimulated or no movement at all OR not feeding at all for at least 12 hours. |
| Cases of hypothermia identified | Day 1 (or as soon as possible after notification of birth), 3, 7, 14, and 28 of life | Defined using ThermoSpot as: 1. Moderate hypothermia: pale green and red face (35ºC to 36ºC) 2. Severe hypothermia: black face (\<35ºC) |
| Neonatal mortality | Day 1 (or as soon as possible after notification of birth), 3, 7, 14, and 28 of life | Death from any cause within the first 28 days of life |
| Number of LBW babies identified | Day 1 (or as soon as possible after notification of birth), 3, 7, 14, and 28 of life | LBW defined as: \<2500 grams at first weighing |
| Health facility use | Day 1 (or as soon as possible after notification of birth), 3, 7, 14, and 28 of life | — |
| Cases of hyperthermia identified | Day 1 (or as soon as possible after notification of birth), 3, 7, 14, and 28 of life | Defined using ThermoSpot as: Hyperthermia: blue face (\>39ºC) |
Countries
Kenya